Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer
Haojie Huang
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorChristopher P. Reed
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorAderonke Mordi
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorGwen Lomberk
Tumor Biology Program, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorLiang Wang
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorViji Shridhar
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorLynn Hartmann
Department of Medical Oncology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorRobert Jenkins
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorCorresponding Author
David I. Smith
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Foundation, 200 First Street S.W., Rochester, MN 55905.Search for more papers by this authorHaojie Huang
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorChristopher P. Reed
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorAderonke Mordi
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorGwen Lomberk
Tumor Biology Program, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorLiang Wang
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorViji Shridhar
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorLynn Hartmann
Department of Medical Oncology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorRobert Jenkins
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Search for more papers by this authorCorresponding Author
David I. Smith
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota
Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Foundation, 200 First Street S.W., Rochester, MN 55905.Search for more papers by this authorAbstract
We previously showed that FRA7G, an aphidicolin-inducible common fragile site at 7q31.2, colocalized with the common region of loss of heterozygosity (LOH) in a number of different tumors. Based on the sequence analysis of 150 Kb in the FRA7G region, we identified four new polymorphic microsatellite markers. In this article, we have used these four microsatellite markers and eight additional markers from 7q22–32 to analyze the breakage and loss of the region surrounding FRA7G in 49 invasive epithelial ovarian cancers and three borderline ovarian tumors. No allelic loss was detected in the ovarian tumors of borderline malignancy, but 71% (35/49) of the invasive tumors showed LOH at one or more loci in the region analyzed. Of the 12 markers analyzed, most of the markers exhibiting a high frequency of LOH were within FRA7G, and the highest frequency of LOH was seen with the new marker 7G14 (37%, 15/41). Breakpoint analysis in tumors with LOH demonstrated that the frequent loss of DNA sequences seen within the FRA7G region was due to frequent small interstitial deletions and not a result of loss of the whole fragile site region. These findings indicate that FRA7G does play a role in the breakage and loss of 7q sequences in invasive ovarian cancer. In addition, the newly identified markers enable us to further delineate a smallest common region of loss in invasive ovarian tumors to a 150-Kb region flanked by markers D7S486 and 7G14. Genes Chromosomes Cancer 24:48–55, 1999. © 1999 Wiley-Liss, Inc.
REFERENCES
- Achille A, Biasi MO, Zamboni G, Bogina G, Magalini AR, Pederzoli P, Perucho M, Scarpa A. 1996. Chromosome 7q allelic losses in pancreatic carcinoma. Cancer Res 56: 3808–3813. Medline
- Cancer Committee of the International Federation of Gynecology and Obstetrics. 1986. Staging Announcement: FIGO Cancer Committee. Gynecol Oncol 25: 383–385.
- Champeme M-H, Bieche I, Beuzelin M, Lidereau R. 1995. Loss of heterozygosity on 7q31 occurs early during breast tumorigenesis. Genes Chromosomes Cancer 12: 304–306. Medline
- Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC, Jenkins RB. 1993. Human epithelial ovarian cancer allelotype. Cancer Res 53: 2393–2398. Medline
- Cohen S, Lavi S. 1996. Induction of circles of heterogeneous sizes in carcinogen-treated cells: Two-dimensional gel analysis of circular DNA molecules. Mol Cell Biol 16: 2002–2014. Medline
- Cohen S, Regev A, Lavi S. 1997. Small polydispersed circular DNA (spcDNA) in human cells: association with genomic instability. Oncogene 14: 977–985. Medline
- Devilee P, Hermans J, Eyfjord J, Borresen A-L, Lidereau R, Sobol H, Borg A, Cleton-Jansen A-M, Olah E, Cohen BB, Scherneck S, Hamann U, Peterlin B, Caligo M, Bignon Y-J, Maugard CH, the Breast Cancer Somatic Genetics Consortium. 1997. Loss of heterozygosity at 7q31 in breast cancer: Results from an international collaborative study group. Genes Chromosomes Cancer 18: 193–199. Medline
- Druck T, Kastury K, Hadaczek P, Podolski J, Toloczko A, Sikorshi A, Ohta M, LaForgia S, Lasota J, McCue P, Lubinshi J, Huebner K. 1995. Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas. Cancer Res 55: 5348–5353. Medline
- Edelson MI, Scherer SW, Tsui LC, Welch WR, Bell DA, Berkowitz RS, Mok SC. 1997. Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene 14: 2979–2984. Medline
- Ehlen T, Dubeau L. 1990. Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene 5: 219–223. Medline
- Fu Y-H, Kuhl DPA, Pizzuti A, Pieretti M, Sutcliffe JS, Richards R, Verkerk AJMH, Holden JJA, Fenwick RG Jr, Warren ST, Oostra BA, Nelson DL, Caskey CT. 1991. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell 67: 1047–1058. Medline
- Glover TW, Berger C, Coyle-Morris J, Echo B. 1984. DNA polymerase inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67: 882–890.
-
Huang H,
Qian C,
Jenkins RB,
Smith DI.
1998a.
Fish mapping of YAC clones at human chromosomal band 7q31.2: Identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer.
Genes Chromosomes Cancer
21: 152–159.
Medline
10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- Huang H, Qian J, Proffit J, Wilber K, Jenkins RB, Smith DI. 1998b. FRA7G extends over a broad region: Coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites. Oncogene 16: 2311–2319. Medline
- Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W, Smith DI. 1998. A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 58: 759–766. Medline
- Jones C, Slijepcevic P, March S, Baker E, Langdon WY, Richards RI, Tunnacliffe A. 1994. Physical linkage of the fragile site FRA11B and Jacobsen syndrome chromosome deletion breakpoint in 11q23.3. Hum Mol Genet 3: 2123–2130. Medline
- Knight SJL, Flannery AV, Hirst MC, Campbell L, Christodoulou Z, 1993. Tri-nucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. Cell 74: 127–134. Medline
-
Koike M,
Takeuchi S,
Yokota J,
Park S,
Hatta Y,
Miller CW,
Tsuruoka N,
Koeffler HP.
1997.
Frequent loss of heterozygosity in the region of the D7S523 locus in advanced ovarian cancer.
Genes Chromosomes Cancer
19: 1–5.
Medline
10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- Kuniyasu H, Yasui W, Yokozaki H, Akagi M, Kitahara K, Fujii K, Tahara E. 1994. Frequent loss of heterozygosity of the long arm of chromosome 7 is closely associated with progression of human gastric carcinomas. Int J Cancer 59: 597–600. Medline
- Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L. 1998. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: Evidence for multiple critical loci. Proc Natl Acad Sci USA 95: 3781–3785. Medline
- Lin JC, Scherer SW, Tougas L, Traverso G, Tsui L-C, Andrulis I, Jothy S, Park M. 1996. Detailed deletion mapping with a refined physical map of 7q31 location of a putative tumor suppressor gene for breast cancer in the region of MET. Oncogene 13: 2001–2008. Medline
- Nishizuka S, Tamura G, Terashima M, Satodate R. 1997. Commonly deleted region on the long arm of chromosome 7 in differentiated adenocarcinoma of the stomach. Br J Cancer 76: 1567–1571. Medline
- Ogata T, Ayusawa D, Namba M, Takahashi E, Oshimura M, Oishi M. 1993. Chromosome 7 suppresses indefinite division of nontumorigenic immortalized human fibroblast cell lines KMST-6 and SUSM-1. Mol Cell Biol 13: 6036–6043. Medline
- Panagopoulos I, Pandis N, Thelin S, Petersson C, Mertens F, Borg A, Kristoffersson U, Mitelman F, Aman P. 1996. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res 56: 4871–4875. Medline
- Parrish JE, Oostra BA, Verkerk AJ, Richards CS, Reynolds J, Spikes AS, Shaffer LG, Nelson DL. 1994. Isolation of a GCC repeat showing expansion in FRAXF, a fragile site distal to FRAXA and FRAXE. Nat Genet 8: 229–235. Medline
-
J Sambrook,
EF Fritsch,
T Maniatis, editors.
1989.
Molecular Cloning: A Laboratory Manual.
Cold Spring Harbor, N.Y.:
Cold Spring Harbor Laboratory Press.
10.1111/j.1095-8312.1996.tb01434.x Google Scholar
- Shridhar R, Shridhar V, Wang X, Paradee W, Dugan M, Sarkar F, Wilke C, Glover TW, Vaitkevicius VK, Smith DI. 1996. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res 56: 4347–4350. Medline
- Shridhar V, Wang L, Rosati R, Paradee W, Shridhar R, Mullins C, Sakr W, Grignon D, Miller OJ, Sun QC, Petros J, Smith DI. 1997. Frequent breakpoints in the region surrounding FRA3B in sporadic renal cell carcinomas. Oncogene 14: 1269–1277. Medline
- Smeets DFCM, Scheres JMJC, Hustinx TWJ. 1986. The most common fragile site in man is 3p14. Hum Genet 72: 215–220. Medline
- Sunnerhagen P, Sjoberg RM, Bjursell G. 1989. Increase of extrachromosomal circular DNA in mouse 3T6 cells on perturbation of DNA synthesis: Implications for gene amplification. Somat Cell Mol Genet 15: 61–70. Medline
- Sutherland GR, Hecht F. 1985. Fragile Sites on Human Chromosomes. New York: Oxford University Press.
- Takahashi S, Shan AL. 1995. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 55: 4114–4119. Medline
- Todd S, Franklin WA, Varella-Garcia M, Kennedy T, Killiker CEJr, Hahner L, Anderson M, Wiest JS, Drabkin HA, Gemmill RM. 1997. Homozygous deletions of human chromosome 3p in lung tumors. Cancer Res 57: 1344–1352. Medline
-
van den Berg A,
Buys CH.
1997.
Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development.
Genes Chromosomes Cancer
19: 228–232.
Medline
10.1002/(SICI)1098-2264(199708)19:4<228::AID-GCC4>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- Wang L, Li W, Wang X, Zhang C, Zhang T, Mao X, Wu M. 1996. Genetic alterations on chromosomes 3 and 9 of esophageal cancer tissues from China. Oncogene 12: 699–703. Medline
- Wang L, Darling J, Zhang J-S, Qian C-P, Hartmann L, Conover C, Jenkins RB, Smith DI. 1998. Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact. Oncogene 16: 635–642. Medline
- Wilke CM, Guo S-W, Hall BK, Boldog F, Gemmill RM, Chandrasekharappa SC, Barcroft CL, Drabkin HA, Grover TW. 1994. Multicolor FISH mapping of YAC clones in 3p14 and identification of a YAC spanning both FRA3B and the 7(3;8) associated with renal cell carcinoma. Genomics 22: 319–326. Medline
- Yu S, Mangelsdorf M, Hewett D, Hobson L, Baker E, Eyre H, Lapsys N, le Paslier D, Doggett NA, Sutherland GR, Richards RI. 1997. Human chromosomal fragile site FRA16B is an amplified AT-rich minisatellite repeat. Cell 88: 367–374. Medline
- Yunis JJ, Soreng AL. 1984. Constitutive fragile sites and cancer. Science 226: 1199–1204. Medline
- Zenklusen J, Bieche I, Lidereau R, Conti C. 1994a. (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 91: 12155–12158. Medline
- Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ. 1994b. Loss of heterozygosity in human prostate carcinomas: A possible tumor suppressor gene at 7q31.1. Cancer Res 54: 6370–6373. Medline
- Zenklusen JC, Oshimura M, Barrett JC, Conti CJ. 1994c. Inhibition of tumorigenicity of a murine squamous cell carcinoma (SCC) cell line by a putative tumor suppressor gene on human chromosome 7. Oncogene 9: 2817–2825. Medline
- Zenklusen JC, Thompson JC, Klein-Szanto AJP, Conti CJ. 1995a. Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 1q31.1: Evidence for a broad range tumor suppressor gene. Cancer Res 55: 1347–1350. Medline
- Zenklusen J, Weitzel J, Ball H, Conti C. 1995b. Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Oncogene 11: 359–363. Medline